Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict molecular binding affinity with unmatched speed and accuracy.

A handful of industries are on the verge of explosive growth. These three companies are poised to gain the most.

While institutional money managers have released their Q1 holdings, so has the heart and soul of the AI revolution, NVIDIA. See which six stocks NVIDIA owns.

Traders flagged a key technical level at $4.65 and raised concerns over an outlier patient in the Tupelo trial, with attention now turning to management’s commentary during the earnings call.

They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug development landscape.

Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery.